Video

Dr. Seth weighs in on onabotulinumtoxinA injections in patients with complex medical backgrounds

Author(s):

Urology Times staff

“Botox to [the] bladder has, in some ways, changed the paradigm of treatment for [overactive bladder],” says Jai Seth, MD.

In this video, Jai Seth, MD, discusses the background and objectives of the Neurourology and Urodynamics study, “Intravesical onabotulinumtoxinA injections in patients on antiplatelet and anticoagulation therapy.” Seth is a consultant urological surgeon at St. George’s University hospital, London, UK.

Related Videos
Shot of a doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
Dr Louise Kostos answers a question during a Zoom video interview
Illustration of prostate | Image Credit: © Judith - stock.adobe.com
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Related Content
FDA greenlights pivotal trial of Voro Urologic Scaffold for postprostatectomy SUI
March 4th 2025

FDA greenlights pivotal trial of Voro Urologic Scaffold for postprostatectomy SUI

Hannah Clarke
The ARID II trial is assessing the safety and effectiveness of the device in men who are scheduled to undergo robotic-assisted radical prostatectomy.
Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
March 21st 2022

Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

Urology Times staff
“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
Survey data highlights substantial impact of postpartum incontinence
February 11th 2025

Survey data highlights substantial impact of postpartum incontinence

Hannah Clarke
Overall, 85% of respondents indicated they experienced frequent bladder leaks.
Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB
March 18th 2022

Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB

Urology Times staff
“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.
ROBUST I: Optilume maintains durable efficacy, safety for urethral strictures
January 20th 2025

ROBUST I: Optilume maintains durable efficacy, safety for urethral strictures

Hannah Clarke
Functional success was achieved in 58% of patients at 5-year follow-up.
Sunobinop shows promise in phase 1b trial for overactive bladder
January 7th 2025

Sunobinop shows promise in phase 1b trial for overactive bladder

Hannah Clarke
Sunobinop resulted in a reduction in urinary urgency, urinary frequency, and incontinence episodes over the treatment period compared with placebo.
© 2025 MJH Life Sciences

All rights reserved.